Medical management of colorectal liver metastasis

Interventional Oncology: Principles and Practice

Volumn , Issue , 2008, Pages 222-242

  Ma, Wen W ^a   Messersmith, Wells A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650985146     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511722226.020     Document Type: Chapter

References (154)

1. American Cancer Society. Cancers Facts & Figures 2005, ed. 1 Atlanta: American Cancer Society, 2005.
2. Gilbert JM. Distribution of metastases at necropsy in colorectal cancer. Clin Exp Metastasis, 1983; 1(2): 97-101.
3. Tong D, Russell AH, Dawson LE, et al. Second laparotomy for proximal colon cancer. sites of recurrence and implications for adjuvant therapy. Am J Surg, 1983; 145(3): 382-386.
4. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol, 1997 15(3): 938-946.
5. Adam R. Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol, 2003; 14 Suppl 2: ii13-16.
6. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg, 2004; 240(4): 644-657; discussion 657-658.
7. Stangl R, Altendorf-Hofmann A, Charnley RM, et al. Factors influencing the natural history of colorectal liver metastases. Lancet, 1994; 343(8910): 1405-1410.
8. Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg, 1995; 19(1): 59-71.
9. LeonardGD, Brenner B, and Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol, 2005; 23(9): 2038-2048.
10. Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal meta-analysis collaboration. Cochrane Database Syst Rev (2) (2): CD001545, 2000.
11. Meyerhardt JA and Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med, 2005; 352(5): 476-487.
12. Rustum YM. Thymidylate synthase: A critical target in cancer therapy? Front Biosci, 2004; 9: 2467-2473.
13. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol, 1991; 9(11): 1967-1972.
14. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol, 1987; 5(10): 1559-1565.
15. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol, 1997; 15(2): 808-815.
16. Lokich JJ, Moore CL, and Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration: Analysis of five standard chemotherapy regimens in three common tumors. Part one. Model projections for cost based on charges. Cancer, 1996; 78(2): 294-299.
17. Lokich JJ, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration. Part two. Use of charges versus reimbursement for cost basis. Cancer, 1996; 78(2): 300-303.
18. Kohne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group study 40952. J Clin Oncol, 2003; 21(20): 3721-3728.
19. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16(1): 301-308.
20. Meropol NJ. Turning point for colorectal cancer clinical trials. J Clin Oncol, 2006; 24(21): 3322-3324.
21. Milano G, Ferrero JM, and Francois E. Comparative pharmacology of oral fluoropyrimidines: A focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer, 2004; 91(4): 613-617.
22. PentheroudakisGandTwelves C. The rational development of capecitabine from the laboratory to the clinic. Anticancer Res, 2002; 22(6B): 3589-3596.
23. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol, 2001; 19(21): 4097-4106.
24. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol, 2001; 19(8): 2282-2292.
25. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, Phase III trials. Br J Cancer, 2004; 90(6): 1190-1197.
26. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 2002; 20(17): 3605-3616.
27. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 2002; 20(17): 3617-3627.
28. Tsunoda A, Shibusawa M, Tsunoda Y, et al. Antitumor effect of S-1 onDMHinduced colon cancer in rats. Anticancer Res, 1998; 18(2A): 1137-1141.
29. Konno H, Tanaka T, Baba M, et al. Therapeutic effect of 1Mtegafur-0. 4M5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. Jpn J Cancer Res, 1999; 90(4): 448-453.
30. Maehara Y, Sugimachi K, Kurihara M, et al. Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group. Gan To Kagaku Ryoho, 1999; 26(4): 476-485.
31. Takemoto H, Fukunaga M, Ooshiro R, et al. A case of peritoneal dissemination disappeared by CPT-11+TS-1 combination chemotherapy. Gan To Kagaku Ryoho, 2005; 32(11): 1768-1770.
32. Nakao K, Tsunoda A, Amagasa H, et al. A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11. Gan To Kagaku Ryoho, 2006; 33(1): 109-112.
33. Kanazawa S, Seo A, Tokura N, et al. Liver metastasis from sigmoid colon cancer with peritoneal dissemination showed a complete response to TS-1. Gan To Kagaku Ryoho, 2006; 33(1): 113-117.
34. Ward S, Kaltenthaler E, Cowan J, et al. Clinical and costeffectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: Systematic review and economic evaluation. HealthTechnol Assess, 2003; 7(32): 1-93.
35. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol, 2004; 22(11): 2084-2091.
36. Bennouna J, Perrier H, Paillot B, et al. A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer, 2006; 94(1): 69-73.
37. Ward S, Kaltenthaler E, Cowan J, et al. Clinical and costeffectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: Systematic review and economic evaluation. HealthTechnol Assess, 2003; 7(32): 1-93.
38. Jansman FG, Postma MJ, van Hartskamp D, et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther, 2004; 26(4): 579-589.
39. Hieke K, Kleeberg UR, Stauch M, et al. Costs of treatment of colorectal cancer in different settings in Germany. Eur J Health Econ, 2004; 5(3): 270-273.
40. Faithfull S and Deery P. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. Eur J Oncol Nurs, 2004; 8 Suppl 1: S54-62.
41. Pizzolato JF and Saltz LB. The camptothecins. Lancet, 2003; 361(9376): 2235-2242.
42. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 1998; 352(9138): 1413-1418.
43. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 1998; 352(9138): 1407-1412.
44. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 2000; 343(13): 905-914.
45. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet, 2000; 355(9209): 1041-1047.
46. Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res, 1994; 54(14): 3723-3725.
47. Gupta E, Wang X, Ramirez J, et al. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol, 1997; 39(5): 440-444.
48. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol, 2004; 22(8): 1382-1388.
49. Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther, 2002; 1(3): 227-235.
50. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol, 1998; 16(8): 2739-2744.
51. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol, 1998; 9(1): 105-108.
52. Levi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer, 1993; 29A(9): 1280-1284.
53. Plasencia C, Taron M, Martinez E, et al. Downregulation of thymidylate synthase gene expression after oxaliplatin administration: Implications for the synergistic activity of sequential oxaliplatin/5FU in sensitive and 5FU-resistant cell lines. Proc Am Assoc Cancer Res, 2001; 42: 508, (abstr).
54. Fischel JL, Formento P, Ciccolini J, et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer, 2002; 86(7): 1162-1168.
55. Yeh KH, Cheng AL, Wan JP, et al. Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. Anticancer Drugs, 2004; 15(4): 371-376.
56. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol, 2003; 21(11): 2059-2069.
57. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol, 2000; 18(1): 136-147.
58. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol, 2002; 21: (abstr 512).
59. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 2000; 18(16): 2938-2947.
60. Shields AF, Zalupski MM, Marshall JL, et al. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: A phase II trial. Cancer, 2004; 100(3): 531-537.
61. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: Final results of the southern Italy Cooperative Oncology Group trial 0108. Cancer, 2005; 104(2): 282-289.
62. Feliu J, Salud A, Escudero P, et al. XELOX(capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer, 2006; 94(7): 969-975.
63. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol, 1998; 25(2 Suppl 5): 4-12.
64. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol, 1998; 9(10): 1053-1071.
65. Grothey A: Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol, 2003; 30(4 Suppl 15): 5-13.
66. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2005; Vol 23, No 16S, Part I of II (June 1 Supplement): 3501 (abstr).
67. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol, 2004; 22(2): 229-237.
68. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico dell'Italia Meridionale. J Clin Oncol, 2005; 23(22): 4866-4875.
69. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22(1): 23-30.
70. Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). ProcAm Soc Clin Oncol, 2003; 22: (Abstr 1022).
71. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): A multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer, 2006; 94(6): 798-805.
72. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 2004; 22(7): 1209-1214.
73. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004; 350(23): 2335-2342.
74. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Highdose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Vol 23, No 16S, Part I of II (June 1 Supplement), 2005, 2 (abstr).
75. Saltz LB, Meropol NJ, Loehrer PJ S, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 2004; 22(7): 1201-1208.
76. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004; 351(4): 337-345.
77. Saltz L, Rubin MS, and Hochster HS. Cetuximab (IMCC225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol, 2001; 20: (abstr 7).
78. Carpenter G and Cohen S: Epidermal growth factor. J Biol Chem, 1990; 265(14): 7709-7712.
79. Real FX, Rettig WJ, Chesa PG, et al. Expression of epidermal growth factor receptor in human cultured cells and tissues: Relationship to cell lineage and stage of differentiation. Cancer Res, 1986; 46(9): 4726-4731.
80. Baselga J: Targeting the epidermal growth factor receptor: A clinical reality. J Clin Oncol, 2001; 19(18 Suppl): 41S-44S.
81. Yasui W, Sumiyoshi H, Hata J, et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res, 1988; 48(1): 137-141.
82. Messa C, Russo F, Caruso MG, et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol, 1998; 37(3): 285-289.
83. Porebska I, Harlozinska A, and BojarowskiT. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol, 2000; 21(2): 105-115.
84. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 1995; 19(3): 183-232.
85. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer, 1993; 71(8): 2454-2460.
86. Hemming AW, Davis NL, Kluftinger A, et al. Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and ki-67. J Surg Oncol, 1992; 51(3): 147-152.
87. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist, 2002; 7 Suppl 4: 2-8.
88. Fan Z, Baselga J, Masui H, et al. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res, 1993; 53(19): 4637-4642.
89. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res, 1995; 1(11): 1311-1318.
90. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res, 2002; 8(5): 994-1003.
91. Badarinath S, Mitchell EO, HennisCD, et al. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004; Vol 22, No 14S (July 15 Supplement): 3531 (abstr).
92. Perez-Soler R and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol, 2005; 23(22): 5235-5246.
93. Lenz H, Mayer RJ, and Gold PJ. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Journal of Clinical Oncology, ASCOAnnual Meeting Proceedings (Post-Meeting Edition), 2004; Vol 22, No 14S (July 15 Supplement): 3510 (abstr).
94. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 2005; 23(9): 1803-1810.
95. Gibson TB, Ranganathan A, and Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer, 2006; 6(1): 29-31.
96. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis. N Engl J Med, 1995; 333(26): 1757-1763.
97. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: A new paradigm for combination therapy. Nat Med, 2001; 7(9): 987-989.
98. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med, 2003; 9(6): 669-676.
99. Ferrara N, Hillan KJ, and Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun, 2005; 333(2): 328-335.
100. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol, 2003; 21(1): 60-65.
101. Giantonio BJ, Catalano PJ, MeropolEP, et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. 2005 ASCO Gastrointestinal Cancers Symposium; Abstract 169a (abstr).
102. Giantonio BJ, Catalno PJ, O'Dwyer PJ, et al. Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group's study E3200. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I Vol 2006; 24, No 18S (June 20 Supplement): 3538 (abstr).
103. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg, 1996; 224(4): 509-520; discussion 520-522.
104. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol, 1999; 10(6): 663-669.
105. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol, 2001; 8(4): 347-353.
106. Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741. Ann Oncol, 2005; 16(3): 425-429.
107. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol, 2006; 13(1): 58-65.
108. Wein A, Riedel C, Kockerling F, et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol, 2001; 12(12): 1721-1727.
109. Gaspar EM, Artigas V, Montserrat E, et al. Single centre study of L-OHP/5-FU/LV before liver surgery in patients with NOT optimally resectable colorectal cancer isolated liver metastases. Proc Am Soc Clin Oncol, 2003; 22: (abstr 1416).
110. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol, 2005; 23(36): 9243-9249.
111. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol, 2004; 15(6): 933-939.
112. Quenet F, Nordlinger B, Rivoire M, et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (FOLFIRINOX): A prospective phase II trial. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004; Vol 22, No 14S (July 15 Supplement): 3613 (abstr).
113. De La Camara J, Rodriguez J, Rotellar F, et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004; Vol 22, No 14S (July 15 Supplement): 3593.
114. Gruenberger T, Gruenberger B, and Scheithauer W. Neoadjuvant therapy with bevacizumab. J Clin Oncol, 2006; 24(16): 2592-2593; author reply, 2593-2594.
115. Fowler WC, Eisenberg BL, and Hoffman JP. Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma. J Surg Oncol, 1992; 51(2): 122-125.
116. Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer. J Clin Oncol, 2002; 20(19): 4006-4014.
117. Masi G, Allegrini G, Cupini S, et al: First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXFIRI): Results of a phase II study with a simplified biweekly schedule. Ann Oncol, 2004; 15(12): 1766-1772.
118. Ellis LM, Curley SA, and Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol, 2005; 23(22): 4853-4855.
119. Chong G, Cunningham D. Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol, 2005; 23(36): 9063-9066.
120. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol, 2005; 16(8): 1311-1319.
121. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg, 2003; 7(8): 1034-1044.
122. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol, 2004; 15(3): 460-466.
123. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol, 2006; 24(13): 2065-2072.
124. Hurwitz H, Fehrenbacjer T, Cartwright T, et al. Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004; Vol 22, No 14S (July 15 Supplement): 3702 (abstr).
125. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg, 1999; 230(3): 309-318; discussion 318-321.
126. Figueras J, Valls C, Rafecas A, et al. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg, 2001; 88(7): 980-985.
127. Andre T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol, 2003; 21(15): 2896-2903.
128. Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol, 2005; 16(4): 549-557.
129. Poplin EA, Benedetti JK, Estes NC, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol, 2005; 23(9): 1819-1825.
130. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med, 2005; 352(26): 2696-2704.
131. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 2004; 350(23): 2343-2351.
132. Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP protocol C-07. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2005; Vol 23, No 16S, Part I of II (June 1 Supplement): 3500 (abstr).
133. Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2005; Vol 23, No 16S, Part I of II (June 1 Supplement): 8 (abstr).
134. Ychou M, Raoul JL, Douillard JY, et al: A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2005; Vol 23, No 16S, Part I of II (June 1 Supplement): 3502 (abstr).
135. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004; Vol 22, No 14S (July 15 Supplement): 3500 (abstr).
136. Portier G, Rougier P, Milan C, et al. Adjuvant systemic chemotherapy (CT) using 5-fluorouracil (FU) and folinic acid (FA) after resection of liver metastases (LM) from colorectal (CRC) origin. Results of an intergroup phase III study (trial FFCD-ACHBTH-AURC 9002). Proc Am Soc Clin Oncol, 2002; 21: (abstr 528) (abstr).
137. Nordlinger B, Sorbye H, Debois M, et al. Feasibility and risks of pre-operative chemotherapy (CT) with FOLFOX 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC intergroup randomized phase III study 40983. Journal of Clinical Oncology, ASCOAnnual Meeting Proceedings, Vol 2005; 23, No 16S, Part I of II (June 1 Supplement): 3528 (abstr).
138. Llovet JM, Burroughs A, and Bruix J. Hepatocellular carcinoma. Lancet, 2003; 362(9399): 1907-1917.
139. Bruix J, Sala M, and Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology, 2004; 127(5 Suppl 1): S179-88.
140. Diculescu M, Atanasiu C, Arbanas T, et al. Chemoembolization in the treatment of metastatic ileocolic carcinoid. Rom J Gastroenterol, 2002; 11(2): 141-147.
141. Salman HS, Cynamon J, Jagust M, et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer, 2002; 2(3): 173-179.
142. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: The M. D. Anderson experience. Cancer J, 2003; 9(4): 261-267.
143. Sullivan KL. Hepatic artery chemoembolization. Semin Oncol, 2002; 29(2): 145-151.
144. Sanz-Altamira PM, Spence LD, Huberman MS, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: A phase II trial. Dis Colon Rectum, 1997; 40(7): 770-775.
145. Tellez C, Benson AB, 3rd, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer, 1998; 82(7): 1250-1259.
146. Leichman CG, Jacobson JR, Modiano M, et al. Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial. Cancer, 1999; 86(5): 775-781.
147. Bavisotto LM, Patel NH, Althaus SJ, et al. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: A phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Clin Cancer Res, 1999; 5(1): 95-109.
148. You YT, Changchien CR, Huang JS, et al. Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer. Int J Colorectal Dis, 2006; 21(1): 33-37.
149. PoonRT, Lau C, YuWC, et al. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: A prospective study. Oncol Rep, 2004; 11(5): 1077-1084.
150. Li X, Feng GS, Zheng CS, et al. Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat withWalker-256 transplanted hepatoma: An experimental study. World J Gastroenterol, 2003; 9(11): 2445-2449.
151. Chung YL, Jian JJ, Cheng SH, et al. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: Implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res, 2006; 12(9): 2706-2715.
152. Roy-Chowdhury S, Peng Y, Wei D, et al. Evaluation of serum vascular endothelial growth factor (VEGF) levels following trans-arterial chemoembolization (TACE) of hepatic malignancies of gastrointestinal (GI) origin. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2005; Vol 23, No 16S, Part I of II (June 1 Supplement): 3087 (abstr).
153. Schwartz JD, Zuo Q, Lehrer D, et al. Serum vascular endothelial growth gactor (VEGF) and hepatocyte growth factor (HGF) are increased following transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC). 2006 ASCO Gastrointestinal Cancers Symposium; abstract No. 218 (abstr).
154. BrittenCD, Finn RS, Gomes AS, et al. Apilot study of IV bevacizumab in hepatocellular cancer patients undergoing chemoembolization. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2005; Vol 23, No 16S, Part I of II (June 1 Supplement): 4138.